| XLS |
|
|
|
|
|
|
|
€ million |
Q3 – 2013 |
Q3 – 2012 |
Jan.–Sept. |
Jan.–Sept. |
|
Profit after tax |
342.5 |
188.7 |
927.6 |
303.3 |
|
Items of other comprehensive income that will not be reclassified to the income statement in subsequent periods: |
|
|
|
|
|
Remeasurement of the net defined benefit liability |
|
|
|
|
|
Changes in remeasurement |
25.2 |
–97.1 |
–18.3 |
–106.9 |
|
Deferred taxes |
–4.0 |
16.6 |
2.7 |
14.7 |
|
Changes recognized in equity |
21.2 |
–80.5 |
–15.6 |
–92.2 |
|
|
21.2 |
–80.5 |
–15.6 |
–92.2 |
|
Items of other comprehensive income that may be reclassified to the income statement in subsequent periods: |
|
|
|
|
|
Available-for-sale financial assets |
|
|
|
|
|
Fair value adjustments |
0.8 |
1.1 |
1.6 |
1.2 |
|
Reclassification to income statement |
– |
– |
– |
– |
|
Deferred taxes |
–0.1 |
– |
–0.6 |
– |
|
Changes recognized in equity |
0.7 |
1.1 |
1.0 |
1.2 |
|
Derivative financial instruments |
|
|
|
|
|
Fair value adjustments |
37.6 |
7.9 |
81.3 |
–43.1 |
|
Reclassification to income statement |
–8.2 |
10.7 |
–13.1 |
65.0 |
|
Deferred taxes |
–8.8 |
–3.0 |
–16.0 |
–1.8 |
|
Changes recognized in equity |
20.6 |
15.6 |
52.2 |
20.2 |
|
Exchange differences on translating foreign operations |
|
|
|
|
|
Changes taken directly to equity |
–61.2 |
–8.6 |
–138.6 |
33.4 |
|
Reclassification to income statement |
– |
– |
–7.6 |
– |
|
Changes recognized in equity |
–61.2 |
–8.6 |
–146.2 |
33.4 |
|
|
–39.9 |
8.1 |
–93.0 |
54.8 |
|
Other comprehensive income |
–18.7 |
–72.4 |
–108.6 |
–37.4 |
|
Comprehensive income |
323.8 |
116.4 |
819.0 |
265.9 |
|
of which attributable to Merck KGaA shareholders |
324.9 |
112.5 |
820.0 |
258.0 |
|
of which attributable to non-controlling interest |
–1.1 |
3.9 |
–1.0 |
7.9 |
back
